Document is current
Any future updates will be listed below
-
Authors
Kanaya, Minoru https://orcid.org/0000-0002-0035-8657
Onozawa, Masahiro https://orcid.org/0000-0001-9267-2864
Matsukawa, Toshihiro
Miyashita, Naoki
Fujii, Fumiaki https://orcid.org/0009-0001-5270-0362
Yoshida, Shota
Nagai, Jun
Aiba, Masayuki
Hidaka, Daisuke
Hashiguchi, Junichi
Senjo, Hajime
Igarashi, Tetsuyuki https://orcid.org/0000-0003-0099-225X
Chiba, Masahiro
Yamamoto, Satoshi
Shimizu, Taku
Ishio, Takashi
Yokoyama, Shota
Ebata, Ko
Iyama, Satoshi
Oyake, Tatsuo
Kondo, Takeshi https://orcid.org/0000-0001-7455-5824
Teshima, Takanori https://orcid.org/0000-0002-0941-271X
- License Information
-
More Information
Article History
Received: 12 May 2025
Revised: 12 June 2025
Accepted: 24 June 2025
First Online: 3 July 2025
Competing interests
: MK's spouse is an employee of AbbVie GK. TK has received honoraria from Astellas Pharma, AbbVie, Amgen, Kyowa Kirin, Nippon Shinyaku, Ono Pharmaceutical, Otsuka Pharmaceutical, Novartis, Pfizer, and Bristol-Myers Squibb; and consultancy fees from Otsuka Pharmaceutical. TT has received honoraria from Abbvie, Astellas, AstraZeneca, Novartis, Bristol-Myers Squibb, Gilead, Nippon Shinyaku, Kyowa Kirin, Janssen, and research funding from LUCA Science, Priothera SAS, Pharma Essentia Japan, Abbvie, IQVIA, CSL Behring, Cmic, Gilead, Novartis, Janssen, Chugai, Kyowa Kirin, International Advanced Medical Organization, and subsidy or donation from Chugai, Kyowa Kirin, Sumitomo Pharma.
